Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
Wennuan LiuJun HouJacqueline PetkewiczRong NaChi-Hsiung WangJishan SunJohnie GallagherYedida Y BogachkovLaura SwensonMaryAnn RegnerW Kyle ResurreccionWilliam B IsaacsCharles B BrendlerSusan CrawfordS Lilly ZhengBrian T HelfandJianfeng XuPublished in: The Prostate (2020)
The probe panel can detect CNAs in trace amounts of tumor DNA from biopsies or surgical tissues at the time of diagnosis or surgery. CNAs independently predict metastatic/lethal cancer, particularly among men with clinically low-risk disease at diagnosis. If validated, this may improve current abilities to assess tumor aggressiveness.
Keyphrases
- copy number
- prostate cancer
- mitochondrial dna
- circulating tumor
- genome wide
- cell free
- single molecule
- living cells
- minimally invasive
- squamous cell carcinoma
- small cell lung cancer
- quantum dots
- dna methylation
- radical prostatectomy
- gene expression
- coronary artery bypass
- squamous cell
- nucleic acid
- heavy metals
- acute coronary syndrome
- young adults
- risk assessment
- coronary artery disease
- fluorescent probe
- surgical site infection
- percutaneous coronary intervention
- atrial fibrillation
- childhood cancer